Sarcoma Alliance for Research through Collaboration

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sarcoma Alliance for Research through Collaboration sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).

20 total trials 2 currently recruiting 12 completed early-phase tilt top decile by trial count

Sarcoma Alliance for Research through Collaboration: 20 sponsored US clinical trials, 2 recruiting.

Sarcoma Alliance for Research through Collaboration sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 12 completed. 2 of these trials are in Phase 3-4 (later-stage) and 18 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Osteosarcoma Metastatic, with 1 trials.

Top-decile sponsor footprint

Sarcoma Alliance for Research through Collaboration ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 54/100

12 of 14 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

20 total, page 1 of 1

RECRUITING Phase 2

SARC046: A Phase II Trial of Nab-Sirolimus in Patients With Progressing or Symptomatic Epithelioid Hemangioendothelioma

NCT07104331
RECRUITING Phase 2

A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma

NCT06942442
ACTIVE NOT RECRUITING Phase 2

SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

NCT06208748
ACTIVE NOT RECRUITING Phase 3

SARC041: Study of Abemaciclib Versus Placebo in Patients with Advanced Dedifferentiated Liposarcoma

NCT04967521
ACTIVE NOT RECRUITING Phase 2

SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma

NCT04803877
ACTIVE NOT RECRUITING Phase 2

A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity

NCT03092323
COMPLETED Phase 1

SARC037: A Phase I/II Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients

NCT04067115
COMPLETED Phase 2

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

NCT03433183
COMPLETED Phase 2

SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma

NCT02303262
COMPLETED Phase 2

SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas

NCT02301039
COMPLETED Phase 2

SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes

NCT02048371
COMPLETED Phase 1

ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma

NCT02044120
COMPLETED Phase 1

SARC023: Ganetespib and Sirolimus in Patients With MPNST (Malignant Peripheral Nerve Sheath Tumors)

NCT02008877
COMPLETED Phase 2

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

NCT01661283
TERMINATED Phase 3

Study of Dose Escalation Versus no Dose Escalation of Imatinib in Metastatic Gastrointestinal Stromal Tumors (GIST) Patients

NCT01031628
TERMINATED Phase 2

A Placebo-Controlled Study of Saracatinib (AZD0530) in Patients With Recurrent Osteosarcoma Localized to the Lung

NCT00752206
COMPLETED Phase 2

Trial of Dasatinib in Advanced Sarcomas

NCT00464620
COMPLETED Phase 2

Neoadjuvant Imatinib in Dermatofibrosarcoma Protuberans

NCT00243191
COMPLETED Phase 2

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

NCT00282087
COMPLETED Phase 2

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Malignant Peripheral Nerve Sheath Tumors

NCT00304083

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 15
Phase 3 2

Therapeutic Areas

Osteosarcoma Metastatic 1
Soft Tissue Sarcoma of the Extremity 1
GIST 1
Osteosarcoma in Children 1
Clear Cell Sarcoma (CCS) 1
HLA-A*0201 Positive Cells Present 1
Bone Sarcoma 1
Metastatic Leiomyosarcoma 1
Advanced Dedifferentiated Liposarcoma 1
Soft Tissue Sarcoma 1

What is open in the Sarcoma Alliance for Research through Collaboration pipeline

2 recruiting of 20 indexed (10% open); 12 completed (60%).

Phase mix: 2 late (III/IV) vs 18 early (I/II) (early-phase heavy).

Top condition: Osteosarcoma Metastatic (1 trial), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sarcoma Alliance for Research through Collaboration: open-pipeline peers nationwide

Peers matched on 20 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Sarcoma Alliance for Research through Collaboration sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%5%10%15%20% Total trials Recruiting share Sarcoma Alliance for Research through Collaboration59th Medical WingAbiomedAgency for Healthcare Research and Quality (AHRQ)Alliance Foundation TrialsAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)Ascension Health
Sarcoma Alliance for Research through Collaboration sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sarcoma Alliance for Research through Collaboration sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 20 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sarcoma Alliance for Research through Collaboration page

20 registered trials is a research-attention snapshot, not an endorsement of Sarcoma Alliance for Research through Collaboration or any single study.

  • 2 of Sarcoma Alliance for Research through Collaboration's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Osteosarcoma Metastatic is the condition Sarcoma Alliance for Research through Collaboration studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Osteosarcoma Metastatic trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sarcoma Alliance for Research through Collaboration pipeline card: 20 registered trials from official public datasets.Report a data error.